Julia Ernst, MS

Migraine correlated with “abnormal modulation” of visual motion stimuli in different areas of the brain that further related to migraine disability and motion sickness susceptibility, according to findings published in Neurology.

A school-based health and mindfulness program improved objective measurements of sleep over a 2-year period in children from communities of low socioeconomic status, according to findings published in Journal of Clinical Sleep Medicine.

A cerebrospinal fluid alpha-synuclein real-time, quaking-induced conversion assay demonstrated efficacy as a “robust biomarker” for identifying mild cognitive impairment due to probable Lewy body disease, according to researchers.

Aduhelm should not be used to treat cerebral amyloid angiopathy outside a clinical trial due to “substantial uncertainties and concerns” about the agent’s safety and efficacy, according to correspondence published in The Lancet Neurology.

Individuals with a “cognitively active lifestyle” delayed dementia onset up to 5 years compared with individuals who engaged in low levels of cognitive activity, according to findings from a longitudinal cohort study published in Neurology.

Better screening protocols and new, potentially more effective treatments have created “an opportune time” for the implementation of newborn screening for Duchenne muscular dystrophy, according to a viewpoint published in JAMA Neurology.

An updated position statement issued by the American Academy of Neurology about ethical considerations that often arise in the treatment of patients with dementia revises the organization’s statement from 1996 on the same topic.

Consecutive sleep loss predicted poorer daily affective and physical well-being among a large sample of U.S. adults, with well-being declining after one night of sleep loss, according to findings published in Annals of Behavioral Medicine.

Extremely preterm infants with prolonged exposure to opioids and benzodiazepines experienced an increased risk for worse neurodevelopmental outcomes at 2 years’ corrected age, according to results from a cohort study.

Patients with active secondary progressive MS who received high-efficacy therapy experienced relapses less often than those on low-efficacy therapy, according to findings published in Neurology.